@article{67866bc179094190abba1fe7326136c8,
title = "SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses",
abstract = "The emergence of variants of concern, some with reduced susceptibility to COVID-19 vaccines underscores consideration for the understanding of vaccine design that optimizes induction of effective cellular and humoral immune responses. We assessed a SARS-CoV-2 spike-ferritin nanoparticle (SpFN) immunogen paired with two distinct adjuvants, Alhydrogel{\textregistered} or Army Liposome Formulation containing QS-21 (ALFQ) for unique vaccine evoked immune signatures. Recruitment of highly activated multifaceted antigen-presenting cells to the lymph nodes of SpFN+ALFQ vaccinated mice was associated with an increased frequency of polyfunctional spike-specific memory CD4+ T cells and Kb spike-(539–546)-specific long-lived memory CD8+ T cells with effective cytolytic function and distribution to the lungs. The presence of this epitope in SARS-CoV, suggests that generation of cross-reactive T cells may be induced against other coronavirus strains. Our study reveals that a nanoparticle vaccine, combined with a potent adjuvant that effectively engages innate immune cells, enhances SARS-CoV-2-specific durable adaptive immune T cell responses.",
author = "Carmen, {Joshua M.} and Shikha Shrivastava and Zhongyan Lu and Alexander Anderson and Morrison, {Elaine B.} and Sankhala, {Rajeshwer S.} and Chen, {Wei Hung} and Chang, {William C.} and Bolton, {Jessica S.} and Matyas, {Gary R.} and Michael, {Nelson L.} and Joyce, {M. Gordon} and Kayvon Modjarrad and Currier, {Jeffrey R.} and Elke Bergmann-Leitner and Malloy, {Allison M.W.} and Mangala Rao",
note = "Funding Information: Mouse anti-RBD monoclonal antibody was produced under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, Wuhan-Hu-1 with C-Terminal Histidine Tag, Recombinant from HEK293F Cells, NR-52366. SARS-CoV-2 MHC class I tetramers were obtained from the NIH tetramer core facility at Emory, Atlanta. We thank Dr. Wolfgang Leitner, NIAID, NIH for providing valuable comments to the manuscript. This work was supported by Restoral FY20 funds from the US Department of Defense, Defense Health Agency. USUHS Department of Pediatrics RAMP grants PED-86-10342 and NIH R01 AI154619. This work was also partially executed through a cooperative agreement between the US Department of Defense and the Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (W81XWH-18-2-0040). The opinions and assertions expressed herein are those of the authors and are not to be construed as reflecting the views of USUHS, the US Air Force, the US Army, the US Navy, the US military at large, or the US Department of Defense. Title 17 U.S.C. 105 provides that “Copyright protection under this title is not available for any work of the United States Government.” Title 17 U.S.C. 101 defines a “United States Government work” as a work prepared by a military service member or employee of the United States Government as part of that person{\textquoteright}s official duties. Publisher Copyright: {\textcopyright} 2021, This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.",
year = "2021",
month = dec,
doi = "10.1038/s41541-021-00414-4",
language = "English",
volume = "6",
journal = "npj Vaccines",
issn = "2059-0105",
number = "1",
}